Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Go back to Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
(NASDAQ: VTRS) Delayed: 18.48 +0.03 (0.16%)
Previous Close $18.45    52 Week High $ 
Open $18.45    52 Week Low $ 
Day High $18.66    P/E N/A 
Day Low $18.35    EPS $ 
Volume 5,435,602